Navigation Links
Threshold to Host Conference Call to Discuss Results From Clinical Presentations at European Cancer Conference (ECCO)
Date:10/3/2007

REDWOOD CITY, Calif., Oct. 3 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), will host a conference call today at 4:30 p.m. ET to discuss the Phase 2 and Phase 3 presentations that were made at the ECCO proceedings last week.

Joining the Company on the conference call will be Dr. Gabi Chiorean, Assistant Professor of Medicine from the Indiana University Cancer Center in Indianapolis, Indiana. Dr. Chiorean is the principle investigator on Threshold's Phase 2 glufosfamide trial in first-line pancreatic cancer patients, and she was present at ECCO to preside over the Phase 2 poster. Also on the conference call will be Dr. Virginia Langmuir who was the medical monitor for both the Phase 2 and the Phase 3 glufosfamide studies.

To access the live teleconference, dial 888-401-4690. To access the live audio webcast or the subsequent archived recording please log on to the Investor section of the Threshold Pharmaceuticals, Inc. website: http://www.thresholdpharm.com.

About Threshold Pharmaceuticals

Threshold is a biotechnology company focused on the discovery and development of small molecule therapeutics for the potential treatment of cancer. By selectively targeting abnormally-proliferating tumor cells, the Company's drug candidates are designed to be potentially more effective and less toxic to healthy tissues than conventional treatments. For additional information, please visit our website (http://www.thresholdpharm.com).

Contact:

Denise T. Powell

Sr. Director, Corporate Communications

Threshold Pharmaceuticals, Inc.

650-474-8206

dpowell@thresholdpharm.com


'/>"/>
SOURCE Threshold Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Threshold Pharmaceuticals Announces Multiple Presentations on Oncology Pipeline at the 2007 American Association for Cancer Research (AACR) Annual Meeting
2. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
3. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
4. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
5. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
6. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. Tercica to Present at Investment Conferences
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Rosetta Genomics to Webcast Presentation at CE Unterberg, Towbin Emerging Growth Opportunities Conference
11. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... YORK , Jan. 23, 2017 ... detect, and control light. The interaction of these ... used in a wide range of applications. These ... aerospace and defense, telecommunications, and healthcare among others. ... primarily owing to its low power consumption, reliability, ...
(Date:1/24/2017)... VALLEY COTTAGE, New York , January 23, 2017 ... Projected to Witness Sluggish Growth ... world are derived from formulating Active Pharmaceutical Ingredients (API), ... isopropanol, propanol and propylene glycol. Production of ... Asia-Pacific excluding Japan ...
(Date:1/23/2017)... 2017  Therabron Therapeutics, Inc., a clinical-stage biotechnology ... respiratory care, today announced that the European Medicines ... granted Orphan Drug Designation for Therabron,s CG367 program, ... (BOS).  "We are pleased to have ... treat patients diagnosed with BOS following lung transplantation. ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 23, 2017 , ... The Pharmacy and Medically Underserved ... bipartisan original co-sponsorship of nearly one-quarter of the U.S. House of Representatives. The ... Chain Drug Stores (NACDS) strongly backs the legislation. , “NACDS thanks for their ...
(Date:1/24/2017)... ... 23, 2017 , ... The TouchPoint Solution, parent company of ... into the product’s app. The data replicates and validates Co-Founder and Neuropsychologist ... 30 seconds of using Buzzies, people experienced a 74 percent reduction in their ...
(Date:1/23/2017)... York, NY (PRWEB) , ... January 23, 2017 , ... ... announced today that John J. Nelson, a senior accountant at the Firm, will participate ... of Make-A-Wish® Hudson Valley. Over 200 runners will race up 1,576 steps, a vertical ...
(Date:1/23/2017)... FL (PRWEB) , ... January 23, 2017 , ... Wooden and plastic balance boards have ... strength and improve balance. Kumo Board is the first and only balance board ... it to be soft and rigid at the same time as well as skill-level adjustable ...
(Date:1/23/2017)... ... 2017 , ... METTLER TOLEDO has announced the availability of ... PAT Tools . , Crystallization is a common step used during ... Chemists now spend more time developing better intermediate and final crystallization steps. ...
Breaking Medicine News(10 mins):